Mereo BioPharma Confirms ADS Registration Under Exchange Act

TL;DR

**Mereo BioPharma's ADSs are officially registered, confirming compliance and market access.**

AI Summary

Mereo BioPharma Group plc filed an 8-K on January 8, 2024, to disclose that its American Depositary Shares (ADSs), each representing five ordinary shares with a par value of £0.003 per share, are registered under Section 12(b) of the Securities Exchange Act of 1934. This filing confirms the company's compliance with ongoing reporting requirements. For investors, this means Mereo BioPharma continues to meet the standards for public trading on a major exchange, providing transparency and liquidity for its stock.

Why It Matters

This filing confirms Mereo BioPharma's continued compliance with SEC regulations, which is crucial for maintaining its listing on a major exchange and ensuring transparency for investors.

Risk Assessment

Risk Level: low — This filing is a routine compliance update and does not indicate any new financial or operational risks for the company.

Analyst Insight

This filing is a routine compliance update and does not present new information that would warrant immediate buying or selling action. Investors should continue to monitor the company's clinical trial progress and financial results for substantive updates.

Key Numbers

• 5 — Ordinary Shares per ADS (Each American Depositary Share represents five ordinary shares.)
• £0.003 — Par Value per Ordinary Share (This is the nominal value of each ordinary share.)

Key Players & Entities

• Mereo BioPharma Group plc (company) — the registrant filing the 8-K
• American Depositary Shares (other) — the securities registered under Section 12(b)
• £0.003 (dollar_amount) — par value per ordinary share
• January 8, 2024 (date) — date of earliest event reported
• Section 12(b) (other) — section of the Securities Exchange Act of 1934 under which securities are registered

FAQ

Filing Documents

• d100759d8k.htm (8-K) — 30KB
• d100759dex991.htm (EX-99.1) — 22KB
• 0001193125-24-003868.txt ( ) — 230KB
• mreo-20240108.xsd (EX-101.SCH) — 4KB
• mreo-20240108_def.xml (EX-101.DEF) — 15KB
• mreo-20240108_lab.xml (EX-101.LAB) — 25KB
• mreo-20240108_pre.xml (EX-101.PRE) — 16KB
• d100759d8k_htm.xml (XML) — 6KB

01

Item 7.01 Regulation FD Disclosure. Press Release On January 8, 2024, Mereo BioPharma Group plc (the "Company") issued a press release providing an update on its pipeline programs as well as an update on recent corporate developments. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. Domestic Issuer Status The Company will begin to file periodic reports and registration statements on U.S. domestic issuer forms with the U.S. Securities and Exchange Commission, which are more detailed and extensive in certain respects, and which must be filed more promptly, than the forms available to a "foreign private issuer" as defined in Rule 405 under the Securities Act of 1933, as amended. Prior to January 1, 2024, the Company qualified as a foreign private issuer. Disclosure Channels to Disseminate Information The Company announces material information to the public about the Company, its potential product candidates and its pipeline and other matters through a variety of means, including filings with the U.S. Securities and Exchange Commission, press releases, public conference calls, the Company's website (www.mereobiopharma.com) and the investor relations section of its website (www.mereobiopharma.com/investors/overview), in order to achieve broad, non-exclusionary distribution of information to the public. The Company encourages investors and others to review the information it makes public in these locations, as such information could be deemed to be material information. This list of communication channels may be updated from time to time. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of t

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release, dated January 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. MEREO BIOPHARMA GROUP PLC Date: January 8, 2024 By: /s/ Christine Fox Name: Christine Fox Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR